Series C is led by Koch Disruptive Technologies and includes Bristol Myers Squibb, DFJ Growth, Willett Advisors and existing investors Eclipse, Dech...
Under the collaboration, Boostimmune will have access to WuXi XDC's fully integrated, one-stop bioconjugate platform and extensive expertise in industry-le...
The GMP release of its first DS facility in China enhances WuXi Vaccines' capability in providing global partners with comprehensive end-to-end solutions, ...
“Samsung Biologics is fully committed to engaging in sustainable business practices for the positive impact it has on our clients, society, and the w...
The company is pleased to disclose its advancement of up to 12 g or more / L expression of recombinant protein - fully folded / biologically active in ferm...
Under the partnership, Pharmadule Morimatsu will provide modular facilities for the WuXi Biologics Singapore CRDMO Center project. This strategic ...
By using this cutting-edge imaging technology in preclinical studies, Oncodesign Services’ team hopes to gain insights of the predictive effectivenes...
Report now includes Scope 3 emissions Employee-driven social responsibility takes precedence as driving force for sustainability activities Goal to red...
As the first facility of Samsung Biologics’ second Bio Campus at its headquarters in Songdo, South Korea, Plant 5 is expected to have the shortest co...
- In response to global clients' increasing demand for contract manufacturing services, WuXi Biologics is expanding its capacity for drug substance a...
Charles River Laboratories International, Inc. (NYSE: CRL) and Wheeler Bio, Inc., a contract development and manufacturing organization (CDMO), annou...
Appointment of Charles River Laboratories ("Charles River") to run Immutep’s preclinical toxicology study evaluating the safety and toxicity of IMP...
The cell & gene therapy (CGT) CDMO has an established global footprint with two GMP manufacturing facilities in China and its headquarters in Vancouver...
WuXi Biologics is the manufacturing partner of InflaRx for Gohibic (vilobelimab), a first-in-class monoclonal anti-C5a antibody. InflaRx received emerge...
© 2025 Biopharma Boardroom. All Rights Reserved.
